COMPANY

New Hope, Better Life

History

GLOBAL Hugel moving to
the global world

  • 2019
    04
    Filed NDA for Botulax in China
    01
    Completed phase III clinical trial (Bless 1,2) of Botulax in US/Poland/Germany
  • 2018
    12
    Botulax approved in Taiwan
    10
    Established U.S. subsidiary Hugel America Inc
    09
    Launched of premium HA filler 'The Chaeum Style'
    01
    Merger with Hugel Pharma with Hugel Meditec
  • 2017
    12
    Awarded $50 Million Export Tower (54th Trade Day Ceremony, Korea International Trade Association)
    10
    Obtained item permission from Korea Food and Drug Administration (MFDS) for penile enlargement HA filler ‘The Chaeum Shape 10’
    07
    Changed major shareholder (Leguh Issuer Designated Activity Company)
    02
    Obtained permission to market Botulax in Brazil and Mongolia
  • 2016
    12
    Awarded $20 Million Export Tower (on the 53rd Trade Day, Korea International Trade Association)
    11
    Obtained permission to market Botulax in Russia
    10
    Appointed as K-Brain Power by Ministry of Commerce, Industry and Energy
    06
    Obtained indication approval for Botulax® 150 Unit (foot deformity in pediatric cerebral palsy)
    05
    Received IND approval for phase III clinical trial for Botulax® in China
    04
    Obtained additional indication approval for Botulax® 150Unit (Post-stroke upper-limb spasticity)
    03
    Received IND approval for phase III clinical trial for Botulax® in Germany Received IND approval for phase III clinical trial for Botulax® in Poland

EXPAND Hugel to expand business

  • 2015
    12
    Listed on KOSDAQ market Received IND approval for phase III clinical trial for Botulax® in U.S.A
    06
    Entered into partnership with Small Lab Co., Ltd.
    04
    Acquired Hutem, Inc. and changed its name to Hugel Meditec, Inc.
    01
    Launched of Bio Cosmetic WELLAGE
  • 2014
    12
    Awarded the third-generation company excellent in entrepreneurial spirit in 2014 (award by President of the Regional Development Committee in the Presidential committee)
    10
    Obtained item permission from Korea Food and Drug Administration (MFDS) for HA filler ‘The Chaeum SubQ 24'
    09
    Awarded the Grand Prize at the 3rd Gangwon Employment Grand Prize
    06
    Selected as 2014 Best Companies to Work For
    05
    Launched HA Filler The Chaeum (THE CHAEUM)
    04
    Obtained item permission from Korea Food and Drug Administration (MFDS) for HA filler ‘The Chaeum Volus 20' Certified as global small hidden champion INNO-BIZ
    03
    Awarded by President of Kangwon Employers’ Federation on the day of businessman
    01
    Awarded as a Man of Hope Connecting project merit (by Ministry of Commerce, Industry and Energy)
  • 2013
    08
    Completed factory registration at Chuncheon 2nd factory (cGMP / EUGMP standard)
    06
    Received IND approval for phase III clinical trial for post-stroke spasticity (Protocol)
  • 2012
    11
    Obtained additional indication approval for Botulax® (glabellar lines) Obtained IND approval for “The Chaeum Volus 20” HA filler (Protocol)
    07
    Constructed Chuncheon 2nd Plant (cGMP / EUGMP standard) (in Chuncheon G-Tech Village)
    06
    Selected as 2012 Best Companies to Work For
  • 2011
    12
    Received IND approval for phase III clinical trial for pediatric cerebral palsy (Protocol)
    10
    Received KFDA approval for Botulax® 50 units
    09
    Awarded as “Prime Minister Prize of Innovative Product Botulex®” on the Local Development Week in 2011 Received KFDA approval for Botulax® 200 units
    07
    Received IND approval for phase III clinical trial for glabellar lines (Protocol)
    06
    Initiation of approval process for international commercialization
  • 2010
    06
    Commercialization of Botulax® in the domestic market
    03
    Received KFDA approval for Botulax® (blepharospasm)
    02
    Received KFDA approval for Botulax® 200 units export Received CE 1023, European certification for Hyalsense Received EN ISO 13485 certification for medical equipment quality control system

RISE Successful commercialization

  • 2009
    06
    Established the seller company 'Hugel Pharma'
    04
    First export in Japan
    03
    Received KFDA approval for Botulax® export
  • 2008
    12
    Received approval to manufacture pharmaceuticals
    04
    Obtained 3 billion KRW investment in private equity funds through IBK (Industrial Bank of Korea)
  • 2007
    09
    Received IND approval for phase III clinical trial for blepharospasm (Protocol)
  • 2006
    10
    Installed KGMP system at the 1st factory in Techno Park, Chuncheon
    07
    Completed preclinical testing for botulinum toxin type A protein

BEGINNING Successful manufacturing
of botulinum toxin

  • 2005
    10
    Implemented preclinical testing for botulinum toxin type A protein
    07
    Acquired patent for polyacrylamide gel
  • 2003
    09
    Successful protein purification of type A botulinum toxin
    03
    Applied for patent for manufacturing polyacrylamide hydrogel
  • 2002
    11
    Developed polyacrylamide gel (PAAG)
  • 2001
    11
    Established Hugel Inc.